Quarterly report pursuant to Section 13 or 15(d)

Aytu Divestiture - Summary of Income Statement (Details)

v3.20.2
Aytu Divestiture - Summary of Income Statement (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Other (expense) income:        
Change in value of Guarantee $ 0   $ 1,755,000 $ 0
Pediatric Portfolio | Discontinued Operations, Disposed of by Sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Product revenue, net (455,463) $ 3,057,462 (1,172,805) 5,892,537
Operating expenses:        
Cost of product sales 0 1,354,855 0 2,550,199
General and administrative 0 41,374 0 82,747
Sales and marketing 0 2,610,990 0 5,323,616
Amortization expense 0 744,099 0 1,488,199
Impairment of intangible assets 0 1,449,121 0 1,449,121
Change in fair value of contingent consideration 0 284,800 0 444,261
Total operating expenses 0 6,485,239 0 11,338,143
Other (expense) income:        
Change in value of Guarantee 0 0 1,755,000 0
Interest expense, net 0 (238,158) 0 (476,316)
Total other (expense) income 0 (238,158) 1,755,000 (476,316)
(Loss) income from discontinued operations before tax (455,463) (3,665,935) 582,195 (5,921,922)
Income tax expense 0 12,971 0 48,658
(Loss) income from discontinued operations, net of tax $ (455,463) $ (3,678,906) $ 582,195 $ (5,970,580)